APIM Therapeutics has already raised more than EUR 26M from public and private sources since 2010. Current major investors in the company include: Sarsia Seed, Harmonium Invest, Torsen Tankers & Towers, Birk Venture and UNIFOB. The proceeds from the latest financing round are supporting the continued clinical development of ATX-101 and the execution of the Company's current clinical development strategy.
For more information on potential investments, feel free to contact us.